2.905
Nuvation Bio Inc stock is traded at $2.905, with a volume of 6.71M.
It is up +6.02% in the last 24 hours and up +23.62% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$2.74
Open:
$2.77
24h Volume:
6.71M
Relative Volume:
1.11
Market Cap:
$994.30M
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-8.30
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
+5.64%
1M Performance:
+23.62%
6M Performance:
+31.45%
1Y Performance:
+3.75%
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NUVB
Nuvation Bio Inc
|
2.905 | 992.59M | 0 | -75.80M | -68.07M | -0.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.59 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
587.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.68 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.74 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
May-04-22 | Initiated | H.C. Wainwright | Buy |
Oct-15-21 | Resumed | BTIG Research | Buy |
Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
Mar-08-21 | Initiated | BTIG Research | Buy |
Mar-08-21 | Initiated | Cowen | Outperform |
Mar-08-21 | Initiated | Jefferies | Buy |
Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Nuvation Bio Inc. shares fall 1.07% after-hours following multiple analyst presentations. - AInvest
Nuvation Bio (NUVB.N) Plummets 5.3%: What’s Driving the Sudden Downturn? - AInvest
Transcript : Nuvation Bio Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 01 - MarketScreener
Transcript : Nuvation Bio Inc.Special Call - MarketScreener
Nuvation Bio Inc. Could See a Relief Rally From SupportPortfolio Value Report & Consistent Profit Focused Trading Strategies - newsyoung.net
Why Nuvation Bio Inc. stock attracts strong analyst attentionJuly 2025 Gainers & Verified High Yield Trade Plans - thegnnews.com
Detecting support and resistance levels for Nuvation Bio Inc.2025 Analyst Calls & Risk Adjusted Swing Trade Ideas - Newser
What institutional flow reveals about Nuvation Bio Inc.Portfolio Value Report & Low Drawdown Trading Strategies - Newser
Nuvation Bio Inc. stock outlook for YEARLayoff News & Growth Focused Stock Reports - Newser
XTX Topco Ltd Buys 44,979 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
What MACD signals say about Nuvation Bio Inc.July 2025 Price Swings & Capital Efficient Trade Techniques - Newser
Does Nuvation Bio Inc. show high probability of reboundJuly 2025 Patterns & Verified Chart Pattern Trade Signals - Newser
Nuvation Bio's Breakthrough FDA-Approved Iprozy and Its Implications for Biotech Growth - AInvest
Transcript : Nuvation Bio Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Exit strategy if you’re trapped in Nuvation Bio Inc.Volume Spike & Fast Exit Strategy with Risk Control - Newser
Nuvation Bio’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria
Chart Patterns Forming a Bullish Setup in Nuvation Bio Inc.2025 Valuation Update & Reliable Price Breakout Signals - kangso.co.kr
Nuvation Bio’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Technical analysis overview for Nuvation Bio Inc. stockPortfolio Risk Summary & Daily Volume Surge Signals - Newser
Nuvation Bio (NUVB.N) Spikes 11.6% Intraday: A Deep Dive Into the Unusual Move - AInvest
Nuvation Bio (NUVB.N) Surges 12.5%—What’s Fueling the Move? - AInvest
Analyzing recovery setups for Nuvation Bio Inc. investorsCEO Change & Free Community Consensus Stock Picks - Newser
Tools to monitor Nuvation Bio Inc. recovery probabilityChart Pattern Strategy with ROI Focus - Newser
Nuvation Bio Inc. (NYSE:NUVB) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - 富途牛牛
Nuvation Bio (NYSE:NUVB) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Defense World
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates - MSN
Wall Street Zen Downgrades Nuvation Bio (NYSE:NUVB) to Sell - Defense World
Nuvation Bio shares rise 1.30% after-hours after RBC raised its price target to $7. - AInvest
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for IDH1 Mutant Glioma - TipRanks
RBC Raises Price Target on Nuvation Bio to $7 From $6, Keeps Outperform, Speculative Risk - MarketScreener
Nuvation Bio Sees Rapid Adoption of IBTROZI, Reports $1.2M in Q2 2025 Sales and $607.7M in Cash Reserves. - AInvest
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Nuvation Bio Inc (NUVB) Q2 2025 Earnings Call Highlights: Strong IBTROZI Launch and Strategic ... By GuruFocus - Investing.com Canada
Nuvation Bio’s Milestone with FDA Approval of IBTROZI - TipRanks
NUVB Sales Jump 1,043% on Drug Launch - AOL.com
Nuvation Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nuvation Bio Reports 1,043% YoY Sales Growth, Exceeds Revenue Estimates with $4.8 Million in GAAP Revenue - AInvest
Earnings call transcript: Nuvation Bio Q2 2025 sees steady EPS, stock rises - Investing.com
Nuvation Bio Inc. SEC 10-Q Report - TradingView
Nuvation Bio earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q2 Revenue $4.8M - MarketScreener
New Lung Cancer Drug IBTROZI Gains FDA Approval, Reaches 70 Patients in First 7 Weeks - Stock Titan
Nuvation Bio shares rise 1.27% premarket after announcing new data presentations at IASLC 2025 and ESMO 2025. - AInvest
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses - BioSpace
Nuvation Bio Presents New IBTROZI Data at WCLC and ESMO Congresses - AInvest
What are the latest earnings results for Nuvation Bio Inc.Consistent triple-digit returns - Jammu Links News
What makes Nuvation Bio Inc. stock price move sharplyCapitalize on market trends with confidence - Jammu Links News
Nuvation Bio Inc. Stock Analysis and ForecastDiscover undervalued stocks before they soar - Jammu Links News
Nuvation Bio (NUVB.N) Plunges 5.5%: What’s Behind the Sudden Sell-Off? - AInvest
Nuvation Bio Announces Q2 2025 Financial Results and Business Update on August 7, 2025. - AInvest
What catalysts could drive Nuvation Bio Inc. stock higher in 2025Get real-time alerts on top-performing stocks - Jammu Links News
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):